Alphamab Oncology
HKEX:9966
Alphamab Oncology
Income from Continuing Operations
Alphamab Oncology
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alphamab Oncology
HKEX:9966
|
Income from Continuing Operations
-¥210.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Income from Continuing Operations
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Income from Continuing Operations
-¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Income from Continuing Operations
¥1.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Income from Continuing Operations
¥7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
35%
|
CAGR 10-Years
50%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Income from Continuing Operations
¥1.3B
|
CAGR 3-Years
62%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Alphamab Oncology's Income from Continuing Operations?
Income from Continuing Operations
-210.6m
CNY
Based on the financial report for Dec 31, 2023, Alphamab Oncology's Income from Continuing Operations amounts to -210.6m CNY.
What is Alphamab Oncology's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-1%
Over the last year, the Income from Continuing Operations growth was 35%. The average annual Income from Continuing Operations growth rates for Alphamab Oncology have been 21% over the past three years , -1% over the past five years .